We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Drug Blocks Development of Malignant Melanomas

By LabMedica International staff writers
Posted on 14 Feb 2019
Print article
Image: The structure of the NRAS protein (Photo courtesy of Wikimedia Commons).
Image: The structure of the NRAS protein (Photo courtesy of Wikimedia Commons).
A promising experimental drug may prevent growth and spread of malignant melanomas having a mutation in the NRAS gene.

Activating mutations in the NRAS (Neuroblastoma RAS viral oncogene homolog) gene account for 20%–30% of melanoma, but despite decades of research no effective anti-NRAS therapies have been developed.

With this in mind, investigators at Boston University School of Medicine (MA, USA) identified the previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. The protein encoded by STK19 localizes predominantly to the nucleus. Its specific function is unknown, but it is thought that phosphorylation of this protein may be involved in transcriptional regulation.

The investigators reported in the January 31, 2019, online edition of the journal Cell that STK19 phosphorylated NRAS, which enhanced its binding to its downstream effectors and promoted oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N (aspartate (D89) to aspargine) substitution in STK19 - whose alterations were identified in 25% of human melanomas - represented a gain-of-function mutation that interacted better with NRAS to enhance melanocyte transformation. STK19 D89N activation led to skin hyperpigmentation and promoted NRAS-driven melanoma formation in vivo.

In addition, the investigators described the development of the drug ZT-12-037-01 as a specific STK19-targeted inhibitor and showed that it effectively blocked oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.

"This study provides a promising therapeutic strategy for melanoma treatment. Furthermore, the STK19 inhibitor might be a therapeutic option in 25% of all cancers with RAS mutations," said senior author Dr. Rutao Cui, professor of pharmacology and experimental therapeutics at Boston University School of Medicine. "We hope our findings ultimately will be clinically translated into improved care for cancer patients."

Related Links:
Boston University School of Medicine

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.